Theoretical novel medical isotope production with deuterium-tritium fusion technology

The emergence and growth of fusion technology enables investigative studies into its applications beyond typical power production facilities. This study seeks to determine the viability of medical isotope production with the neutrons produced in an example large fusion device. Using FISPACT-II (a nuclear inventory code) and a simulated fusion spectrum, the production yields of a significant number of potentially clinically relevant (both in use and novel) medical isotopes were calculated. Comparative calculations were also conducted against existing production routes.

Depending on the neutron flux of the fusion device, it could be an ideal technology to produce alpha-emitters such as ²¹²Bi/²¹²Pb, it may be able to contribute to the production of ^99mTc/⁹⁹Mo, and could offer an alternative route in the production a few Auger-emitting candidates. There is also a long list of beta-emitting nuclides where fusion technology may be best placed to produce over existing technologies including ⁶⁷Cu, ⁹⁰Y and ⁴⁷Sc.

It is theoretically viable to produce existing and novel medical isotopes with fusion technology. However, a significant number of assumptions form the basis of this study which would need to be studied further for any particular nuclide of interest.